30.11.2021 18:29

Top Research Reports for Mastercard, Pfizer & Nike

Folgen
Werbung
Tuesday, November 30, 2021The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Mastercard Inc. (MA), Pfizer Inc. (PFE), and Nike, Inc. (NKE). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today’s research reports here >>>Shares of Mastercard have outperformed the Zacks Financial Transaction Services industry over the past year (-4.2% vs. -24%). The Zacks analyst believes that Mastercard's profit levels have been rising on the back of higher consumer spending, and is well-poised to gain from steady cash-generating abilities.Strategic acquisitions, alliances and technology upgrades, along with product-diversification and geographic-expansion initiatives bode well for the long term. Mastercard uses acquisitions to supplement its organic efforts and diversify its revenues. A strong capital position enables MA to pursue acquisitions and deploy capital. High expenditures, higher rebates as well as incentives, however, are likely to weigh on Mastercard's margins.(You can read the full research report on Mastercard here >>>)Pfizer shares have gained +48% in the year-to-date period against the Zacks Large-Cap Pharmaceuticals industry’s gain of +16.7%. The Zacks analyst believes that Pfizer’s licensing deals and collaborative agreements are likely to drive growth in the near term.The Consumer Healthcare JV with Glaxo and merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. Strong growth of key brands like Ibrance, Inlyta and Eliquis are also expected to drive sales. PFE’s COVID-19 vaccine has become a key contributor to the top line. Currency headwinds and pricing pressure, however, remains as the top-line headwinds.(You can read the full research report on Pfizer here >>>)Shares of Nike have gained +24.7% in the past six months against the Zacks Shoes and Retail Apparel industry’s gain of +22.7%. The Zacks analyst is impressed with Nike’s product innovation, brand strength and scale of operations.Strong Nike Direct sales, led by the return of traffic to stores and digital momentum aided the fiscal first quarter results. In fiscal 2022, Nike expects consumer demand to remain robust, driven by its strong customer connections and brand momentum. NKE has, however, been battered by supply-chain woes and the closure of Vietnam and Indonesia factories, resulting in product shortages.(You can read the full research report on NIKE here >>>)Other noteworthy reports we are featuring today include Lockheed Martin Corp. (LMT), Micron Technology, Inc. (MU) and Eli Lilly and Co. (LLY).Mark VickerySenior EditorNote: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>Tech IPOs With Massive Profit Potential: Last years top IPOs surged as much as 299% within the first two months. With record amounts of cash flooding into IPOs and a record-setting stock market, this year could be even more lucrative. See Zacks’ Hottest Tech IPOs Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Lockheed Martin Corporation (LMT): Free Stock Analysis Report Mastercard Incorporated (MA): Free Stock Analysis Report NIKE, Inc. (NKE): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Micron Technology, Inc. (MU): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Weiter zum vollständigen Artikel bei "Zacks"
Quelle: Zacks

Nachrichten zu Nike Inc.

  • Relevant
  • Alle
  • vom Unternehmen
  • Peer Group
  • ?

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu Nike Inc.

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
22.12.2021Nike OutperformCredit Suisse Group
22.12.2021Nike BuyJefferies & Company Inc.
21.12.2021Nike OverweightJP Morgan Chase & Co.
06.12.2021Nike BuyGoldman Sachs Group Inc.
12.10.2021Nike BuyGoldman Sachs Group Inc.
22.12.2021Nike OutperformCredit Suisse Group
22.12.2021Nike BuyJefferies & Company Inc.
21.12.2021Nike OverweightJP Morgan Chase & Co.
06.12.2021Nike BuyGoldman Sachs Group Inc.
12.10.2021Nike BuyGoldman Sachs Group Inc.
21.12.2020Nike HoldJefferies & Company Inc.
21.12.2020Nike HoldJefferies & Company Inc.
23.09.2020Nike HoldJefferies & Company Inc.
26.06.2020Nike HoldJefferies & Company Inc.
01.05.2020Nike HoldJefferies & Company Inc.
25.06.2021Nike VerkaufenDZ BANK
23.04.2021Nike VerkaufenDZ BANK
22.12.2020Nike VerkaufenDZ BANK
26.06.2020Nike VerkaufenDZ BANK
04.10.2019Nike UnderperformBNP PARIBAS

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Nike Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"

Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"

Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen
Werbung
Werbung
Werbung
Werbung
Börse Stuttgart Anlegerclub
Werbung

Heute im Fokus

US-Börsen letztlich uneins -- DAX geht schwächer ins Wochenende -- WACKER CHEMIE übertrifft Erwartungen 2021 -- SAP zieht Tempo im Cloudgeschäft an -- JPMorgan, Citigroup, Wells Fargo, DWS im Fokus

AT&T und Dish geben Milliarden für Frequenzen für 5G-Dienste aus. Corona-Impfstoff von Novavax soll ab 21. Februar verfügbar sein. Drägerwerk mit Umsatzeinbußen. Wechsel im AUDI-Aufsichtsrat. Nagarro will Umsatz 2022 um fast ein Drittel steigern. Siemens-Kunden müssen wohl auf Steuerungs-Chips warten. EZB: Lagarde rechnet mit Inflationsrückgang 2022. Streit um Zukunft von Generali-Chef eskaliert im Verwaltungsrat.

Umfrage

Wo steht der DAX zum Jahresende 2022?

finanzen.net zero
finanzen.net zero

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln